MIRM - NASDAQ
Mirum Pharmaceuticals, Inc.
$91.83
-0.016%Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
At a Glance
Live Snapshotmirm
Total Non-Current Liabilities
Last Annual Value
322.32M
3-Year CAGR
30%
5-Year CAGR
45%
10-Year CAGR
18%
Mirum Pharmaceuticals, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 322.32M | 1.2% | 19.6% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 52.35M | 64.9% | 39.9% | 61.9% | |
 ADMA Biologics, Inc. NASDAQ:ADMA | 77.38M | -18.7% | -5.9% | 16.4% | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 1.22B | 9.3% | 23.9% | 69.1% | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 0.00 | N/A | N/A | N/A | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 59.69M | -1.8% | -1.1% | 81.1% | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 164.20M | 93.4% | 41.7% | -33.0% | |
 Travere Therapeutics, Inc. NASDAQ:TVTX | 330.46M | -7.0% | -1.2% | 9.4% | |
 Belite Bio, Inc NASDAQ:BLTE | 188.00K | -31.2% | -64.2% | N/A | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 505.98M | 93.8% | 3.1% | 64.0% |
Mirum Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your MIRM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.